m6A modification on ncRNAs and underlying mechanisms of exercise in the regulation of pathological cardiac remodeling Authors: Gonghua Yin, Xiangfeng He, Nan Chen Published: 2025 ABSTRACT AbstractCardiovascular diseases are a significant menace to human health and life, with pathological cardiac remodeling being a pivotal phase in a spectrum of cardiovascular conditions. In recent years, within the field of epigenetic modifications, N6-methyladenosine (m6A) has risen to prominence as a dynamic and reversible form of RNA methylation. This modification has been shown to modulate the transmission of various signaling pathways and is integral to the pathological remodeling processes of the heart. Advances in molecular biology and the emergence of high-throughput sequencing technologies have facilitated the identification of numerous m6A methylation sites on non-coding RNAs (ncRNAs). These epigenetic alterations have been correlated with a myriad of diseases, notably those associated with cardiac remodeling. Studies have indicated that moderate exercise training can modulate m6A methylation and ncRNA levels across different disease models. Consequently, the aim of this review is to delve into the molecular mechanisms by which m6A methylation affects ncRNAs and to explore the potential pathways through which exercise might exert its influence on the progression of pathological cardiac remodeling. Gaining this insight could uncover novel research targets and pave the way for innovative diagnostic and therapeutic strategies in the management of pathological cardiac remodeling.Keywords: m6A methylation modification, Pathological cardiac remodeling, Non-coding RNAs, Exercise Introduction Cardiac remodeling refers to the heart's adjustments in size, shape, and functional structure in response to physiological or pathological stimuli. Physiological remodeling, such as that occurring during pregnancy or in response to exercise, results in moderate cardiac hypertrophy [1, 2]. Pathological remodeling, however, is a consequence of pathological stimuli, leading to significant changes in the proteins, cellular components, and extracellular matrix. This type of remodeling is characterized by an increase in cardiomyocyte size, substantial cell death, interstitial fibrosis, and a deterioration in the heart's contractile and diastolic functions, as well as its compliance [3]. Pathological remodeling underlies many cardiovascular diseases, disrupting cardiac homeostasis and leading to structural and functional impairments, which can ultimately result in heart failure. Thus, understanding the pathogenesis of pathological cardiac remodeling is crucial for preventing adverse remodeling, preserving heart function, and treating cardiovascular diseases effectively. Epigenetic modifications, including DNA methylation, RNA methylation, histone modifications, and chromatin remodeling, regulate gene expression without altering the DNA sequence and are crucial in the pathogenesis of cardiovascular diseases (CVDs) [4, 5]. Notably, m6A methylation—a prevalent RNA modification in eukaryotes—plays a significant role in the development and progression of cardiovascular diseases (CVDs), including pathological cardiac remodeling, heart failure, atherosclerosis, and congenital heart disease. Its modification sites are predominantly enriched in coding sequences (CDS), 3′-untranslated regions (3′-UTR), near stop codons, and exon junctions, where it influences key RNA processes such as splicing, export, translation, and degradation [6]. Abnormalities in m6A modification are linked to these conditions and can trigger potential risk factors such as obesity, inflammation, hypertension, and type 2 diabetes. In addition, changes in the function and expression of ncRNAs are closely related to the process of pathological cardiac remodeling [7]. Given that m6A methylation modification is also abundant in ncRNAs, it suggests that there is a regulatory relationship between m6A methylation modification and ncRNAs in pathological cardiac remodeling [8]. Long-term exercise training, as a chronic and reversible mechanical stimulus, can effectively slow down the progression of pathological cardiac remodeling. Since the description of "Athlete’s Heart" in the nineteenth century, exercise has been recognized to induce beneficial cardiac adaptations [9]. Moderate physical activity not only helps to reduce the risk of cardiovascular diseases, but also promotes cardiac regeneration through a series of cellular and molecular regulatory mechanisms [10]. This exercise-induced cardiac regeneration is primarily characterized by an increase in the volume of cardiomyocytes, accompanied by a certain degree of an increase in the number of myocardial cells [11]. Studies have demonstrated that exercise can prevent stress-induced anxiety through improving brain RNA methylation, with exercise increasing the levels of methyl donor S-adenosylmethionine (SAM) in the serum and brain, which in turn affects m6A levels [12]. Exercise has been found to regulate the expression of m6A methyltransferases and demethylases, such as METTL3 and FTO, which are crucial for maintaining cardiac function and structure [13, 14]. As research into the role of RNA modifications in cardiovascular diseases deepens, exploring whether exercise can mediate epigenetic modifications and thereby affect cardiac rehabilitation undoubtedly opens up an entirely new field of research. Exploring the intricate dynamics and precise mechanisms of m6A methylation on ncRNAs in the context of exercise-induced cardiac protection is essential for unearthing new therapeutic targets and biomarkers for cardiovascular diseases. This review delineates the impact of m6A modifications in ncRNAs and how exercise might influence these epigenetic changes, offering fresh perspectives for clinical management of cardiac conditions. By dissecting the interplay between m6A methylation and exercise, we aim to enhance diagnostic accuracy and treatment efficacy in cardiovascular medicine. Regulatory molecules of m6A The m6A methylation modification of RNA is a dynamic and reversible epigenetic process mediated by a trio of regulatory molecules termed "Writers", "Erasers", and "Readers" [15, 16]. The “Writers”, comprising methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), and Wilms tumor 1-associated protein (WTAP), form a complex that catalyzes m6A methylation [17–20], with additional methyltransferases like methyltransferase-like 16 (METTL16) and RNA-binding motif protein 15/15B (RBM15) playing roles in the process [21]. “Erasers” such as fat mass and obesity-associated protein (FTO) and AlkB homolog 5 (ALKBH5) demethylate methylated RNA, predominantly within the nucleus [22–24]. "Readers", including the YTH domain family proteins (YTHDFs) like YTHDF1, YTHDF2, and YTHDC1, recognize m6A-modified RNA to modulate RNA metabolism, including translation, degradation, splicing, and nuclear export [25]. Other reader proteins like insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) and heterogeneous nuclear ribonucleoprotein A2B1 (HNRNPA2B1) also contribute to mRNA stability and miRNA processing. Collectively, these molecules regulate RNA function through m6A methylation, highlighting the complexity and significance of this epigenetic mark in gene expression control [26, 27] (Fig. 1). Mechanism of m6A methylation modification. m6A during the transcription process of mRNA, specific methyltransferases (such as METTL3, METTL14, METTL16) recognize and catalyze the methylation of adenosine residues, forming m6A modification. Demethylases (such as FTO, ALKBH5) can remove the m6A modification; mRNAs with m6A modification can be recognized by m6A-binding proteins, which are involved in regulating the further processing and function of mRNA m6A and pathological cardiac remodeling m6A and pathological cardiac hypertrophy Pathological cardiac hypertrophy represents a complex set of compensatory reactions that manifest in the heart when subjected to chronic pressure overload. It serves as the primary pathogenic mechanism behind pathological cardiac remodeling. Continuous pathological cardiac hypertrophy stands as a significant contributor to cardiac contractile dysfunction and heart failure [28]. METTLs’ mediated m6A has distinct effects on pathological cardiac hypertrophy. Mitogen-activated protein kinases (MAPK) are a class of conserved serine/threonine protein kinases and are one of the key regulatory molecules in pathological cardiac hypertrophy and remodelling [29]. m6A methylation levels in the heart increase with hypertrophic stimuli, and METTL3-mediated m6A methylation modification can promote compensatory hypertrophy of cardiomyocytes by activating the expression of MAPK (such as MAP3K6, MAP4K5, MAPK14) without causing cardiac dysfunction. Conversely, the specific knockout of METTL3 in the hearts of mice results in progressive pathological cardiac remodeling and dysfunction over time. It also inhibits the hypertrophic tendency of cardiomyocytes, highlighting the significant role that METTL3 plays in maintaining cardiac function and homeostasis [30]. A novel mechanism underlying the development of pathological cardiac hypertrophy has been uncovered. The enzyme ubiquitin-specific protease 12 (USP12) enhances the expression of METTL3 by boosting the activity of histone acetyltransferase p300, thus facilitating the advancement of pathological cardiac hypertrophy [31]. In addition to the well-known m6A methyltransferase, methyltransferase-like 5 (METTL5) has also been demonstrated to play a role in the regulation of pathological cardiac hypertrophy. Heart-specific knockout of METTL5 induces the occurrence of pathological cardiac remodeling. Further exploration of the molecular mechanism revealed that METTL5 inhibits pathological cardiac hypertrophy by promoting the translation efficiency of the SUZ12–MEF2D axis [32]. The aforementioned two studies furnish fresh evidence supporting the regulation of pathological cardiac hypertrophy through the action of m6A methyltransferases. FTO, as a key m6A demethylase, mediates m6A methylation modifications that can significantly mitigate pathological hypertrophic responses in cardiomyocytes [33]. Furthermore, researchers have discovered that m6A reader proteins also contribute to this process. YTHDF2 can prevent the development of pathological cardiac hypertrophy through its interaction with myosin heavy chain 7 (MYH7) [34]. At present, there are drugs targeting m6A methylation modification that can be used to regulate pathological cardiac hypertrophy. Maslinic acid (MA) exhibits a broad spectrum of pharmacological properties. A recent study has indicated that MA significantly contributes to the prevention of cardiac pathological hypertrophy, both in vitro and in vivo, by suppressing METTL3-mediated m6A methylation modifications [35]. Tanshinone IIA (Tan IIA), an active compound derived from Danshen, has demonstrated the ability to effectively suppress the development of pathological cardiac hypertrophy in both in vivo and in vitro models, which are induced by aortic constriction and angiotensin II. Further investigation revealed that Tan IIA enhances the m6A levels of galectin-3 by suppressing the expression of the demethylase ALKBH5 and diminishing its stability, thus offering a therapeutic approach for pathological cardiac hypertrophy [36]. In summary, m6A methylation modification mainly regulates the occurrence of pathological cardiac hypertrophy through m6A methyltransferases, Both animal experiments and cell research have shown that METTL3, METTL5 can, respectively, initiate/inhibit the occurrence of hypertrophy through the MAPK signaling pathway, the ubiquitin proteasome system, and the SUZ12–MEF2D axis, but the role of other m6A-related enzymes (such as erasers and readers) is still insufficiently studied. Currently, medications that specifically target m6A methylation modifications are being developed for the treatment of pathological cardiac hypertrophy. This advancement has the potential to significantly broaden the spectrum of targeted interventions available for managing pathological cardiac remodeling. m6A and cardiomyocyte death Cell death represents the culmination of the lifecycle for a variety of cells, and cardiomyocytes, being terminally differentiated cells, possess a limited capacity for proliferation. Consequently, the regulation of cardiomyocyte death is of paramount importance for the prevention and treatment of pathological cardiac remodeling. The primary forms of cardiomyocyte death predominantly encompass apoptosis, pyroptosis, and ferroptosis [37]. The regulatory mechanisms of enzymes involved in m6A methylation modifications primarily focus on the control of cardiomyocyte apoptosis. Cardiomyocyte apoptosis represents a form of programmed cell death, and ongoing cardiomyocyte apoptosis is deemed a significant factor in the development of pathological cardiac remodeling following chronic pathological stimulation [38]. Inhibiting the process of cardiomyocyte apoptosis can significantly alleviate pathological cardiac remodeling and heart failure. Academic researchers have documented that WTAP enhances endoplasmic reticulum stress and the rate of cell apoptosis by modulating the m6A methylation level of activating transcription factor 4 (ATF4). Furthermore, the suppression of WTAP expression notably curtails the expression of the pro-apoptotic molecule caspase-3, thereby diminishing cardiomyocyte apoptosis [39]. Yes-associated protein (YAP) serves as a terminal effector molecule within the Hippo signaling pathway. Demethylase FTO has the capacity to remove the m6A methylation modification from its downstream target, Yap, thus mitigating apoptosis in cardiomyocytes induced by hypoxia/reoxygenation [40]. Furthermore, METTL3, ALKBH5, and METTL14 have been established as key regulators of m6A methylation modifications during the process of cardiomyocyte apoptosis [41, 42]. In addition to cardiomyocyte apoptosis, there is currently not much evidence on the role of m6A methylation-related enzymes in other types of cell death mechanisms, and there is still a great prospect in the study of pathological cardiac remodeling, and the molecular mechanisms still need to be further verified by experiments. m6A and cardiac fibrosis Myocardial fibrosis constitutes a crucial mechanism that contributes to the development of pathological cardiac remodeling. It arises from the pathological activation of cardiac fibroblasts and the excessive accumulation of extracellular matrix secreted by these cells. The mechanism of myocardial fibrosis, which is based on epigenetic principles, places m6A methylation modification at a pivotal position [43]. Specifically, m6A methylation can influence the activation and differentiation of cardiac fibroblasts. For instance, METTL3 has been shown to promote the transformation of cardiac fibroblasts into myofibroblasts via activation of the TGF-β/Smad2/3 signaling pathway, thereby exacerbating myocardial fibrosis after myocardial infarction [44]. Similarly, in models of transverse aortic constriction (TAC), METTL3-mediated m6A methylation has been implicated in regulating the extent of fibrosis [45]. However, the role of METTL3 appears to be context-dependent, varying across experimental conditions. In contrast to the pro-fibrotic effects described earlier, one study included in this analysis reported a negative correlation between METTL3 expression and the degree of myocardial fibrosis. These discrepant outcomes may be largely attributable to differences in animal models and induction methods. Specifically, the above-mentioned studies used ligation of the left anterior descending coronary artery (LAD) to induce post-infarction scar formation, while the latter employed TAC to establish a pressure overload-induced cardiac model. These distinct approaches likely account for the observed variations. Additionally, the fibrosis modeling timelines differed—four weeks in the LAD model compared to a shorter period in the TAC model—suggesting that multiple factors may underlie the divergent findings. Together, these observations highlight the complexity of METTL3’s regulatory function in cardiac fibrosis. On the other hand, FTO-mediated m6A demethylation has been consistently reported to attenuate myocardial fibrosis across multiple experimental settings [33, 46]. These findings collectively underscore the potential of targeting m6A methylation as a novel therapeutic strategy for mitigating cardiac fibrosis. m6A and vascular remodeling Vascular remodeling represents a structural and pathological alteration of blood vessels, which is triggered by a variety of factors including fluctuations in blood pressure and blood flow. This process involves modifications in numerous cell types and stands as a hallmark of pathological cardiac remodelling [38]. Numerous studies have confirmed that m6A methylation modification plays a role in the regulation of vascular and cardiac dysfunction under stress conditions. For instance, METTL3 promotes the differentiation of adipose-derived stem cells into vascular smooth muscle cells during hypoxic conditions [47]. The knockdown of METTL3 suppresses the occurrence of ferroptosis in human aortic smooth muscle cells, which are induced by aortic dissection [48]. It is observed that in the context of heart failure, overexpression of FTO has the potential to not only suppress myocardial fibrosis but also to foster angiogenesis [46]. However, the current body of research on m6A-related enzymes during vascular remodeling in cardiac tissue is limited, with only a few samples and models available. Consequently, the depth of understanding in this area remains insufficient. Future studies will require more substantial, direct evidence to fully elucidate the complexity and scientific rigor of these processes (Table 1). Table 1The regulation of m6A methylation modification on pathological cardiac remodelingCategoryIn vitro/in vivom6A enzymeRegulationReferencePathological cardiac hypertrophyIn vitro and in vivoMETTL3Activation[30]In vitro and in vivoMETTL3Activation[31]In vitro and in vivoMETTL5Inhibition[32]In vivoFTOInhibition[33]In vitro and in vivoYTHDF2Inhibition[34]In vitro and in vivoMETTL3Activation[35]In vitro and in vivoALKBH5Activation[36]Myocardial cell deathIn vitro and in vivoWTAPActivation[39]In vitro and in vivoFTOInhibition[40]In vitro and in vivoMETTL3/ALKBH5Activation/inhibition[41]In vitro and in vivoMETTL14Inhibition[42]Cardiac fibrosisIn vitro and in vivoMETTL3Activation[44]In vitro and in vivoMETTL3Inhibition[45]In vivoFTOInhibition[33]In vitro and in vivoFTOInhibition[46]Vascular remodelingIn vitroMETTL3Activation[47]In vitro and in vivoMETTL3Inhibition[48]In vitro and in vivoFTOActivation[46] The regulation of m6A methylation modification on pathological cardiac remodeling m6A on ncRNAs in pathological cardiac remodeling In eukaryotic organisms, RNA molecules that do not code for proteins are generally classified as ncRNAs, among which miRNAs, lncRNAs, circRNAs, and piRNAs are well-known examples. Initially, due to the limitations of biological techniques at the time, ncRNAs were often dismissed as lacking an open reading frame and were deemed "junk RNA" with no apparent biological role [49]. Nevertheless, with the advancement of high-throughput sequencing technologies and the widespread adoption of large-scale transcriptomic analyses, it has become increasingly clear that ncRNAs play a crucial role in regulating cellular and tissue homeostasis via a variety of mechanisms. Posttranscriptional epigenetic modification has received much attention in recent years. Although m6A methylation modification is mostly found in mRNA, it is also found in large numbers in non-coding RNAs [50]. Previous studies have shown that m6A methylation regulates the biological function of non-coding RNAs, which has attracted wide attention in the biomedical field. Considering the significant correlation between m6A methylation modification and ncRNAs, along with its important role in the rational remodeling process of cardiac disease, it is of great significance to study the regulatory mechanisms that govern their interaction. m6A on ncRNAs in pathological cardiac hypertrophy In the pathogenesis of pathological cardiac hypertrophy, various ncRNAs play a regulatory role. For instance, Qi et al. identified several microRNAs—including miR-26b-5p, miR-204-5p, and miR-497-3p—that help maintain cardiac function, promote cardiomyocyte proliferation, and suppress pathological hypertrophy [51]. However, the mechanism through which m6A methylation modification-related enzymes function via ncRNAs in the context of pathological cardiac hypertrophy requires further in-depth investigation and exploration. β-Catenin plays a pivotal role in the canonical Wnt pathway, and the activation of the Wnt/β-catenin signaling cascade can induce a pathological hypertrophic response in myocardial cells [52, 53]. Dickkopf-2 (DKK2), a downstream effector of miR-221/222, also serves as an antagonist to the Wnt/β-catenin signaling pathway. METTL3 can positively regulate the maturation process of miR-221/222, thereby suppressing the expression of DKK2 and activating the Wnt/β-catenin signaling pathway, which in turn promotes pathological cardiac hypertrophy [54]. Additionally, METTL3 interacts with the piRNA CHAPIR–PIWIL4 complex to methylate and upregulate poly ADP-ribose polymerase 10 (Parp10). This action inhibits glycogen synthase kinase-3β (GSK-3β), leading to nuclear accumulation of nuclear factor of activated T-cells 4 (NFATC4), which further drives cardiac hypertrophy [55–57]. Other m6A-related enzymes also modulate ncRNA function in cardiac hypertrophy. Research has indicated that miR-133a enhances cardiac function through the inhibition of pathological cardiac hypertrophy, the promotion of angiogenesis, and the stimulation of myocardial cell proliferation [58]. Under angiotensin II, m6A methylation facilitates the accumulation of the RNA-induced silencing complex (RISC)-AGO2 protein (Argonaute 2, AGO2)-miR-133a complex via IGF2BP2, thus suppressing the development of pathological cardiac hypertrophy [59]. The long non-coding RNA myocardial infarction-associated transcript (lncRNA MIAT) was initially identified in 2006 [60]. Yang et al. established that lncRNA MIAT expression is significantly upregulated in pathologically enlarged hearts. Knockdown of MIAT effectively attenuated the hypertrophic phenotype. Mechanistically, lncRNA MIAT interacts with the m6A reader protein YTHDF2, leading to decreased mRNA stability of carnitine palmitoyltransferase 1a (CPT1a). This suppression of CPT1a expression contributes to the development of pathological cardiac hypertrophy [61]. In summary, m6A methylation exerts multifaceted regulatory effects on ncRNAs during pathological cardiac hypertrophy. Methyltransferases and reader proteins target various ncRNAs and modulate several key signaling pathways, offering novel insights into the epigenetic mechanisms underlying cardiac remodeling. m6A on ncRNAs in myocardial cell death Upon stimulation by pathological factors, myocardial cells undergo extensive cell death, a hallmark of pathological cardiac remodeling. The m6A methylation modification of ncRNAs predominantly governs this process by modulating myocardial cell apoptosis, pyroptosis, and ferroptosis. Apoptosis, an autonomous and orderly cell death program, plays an important role in the occurrence and development of pathological cardiac remodeling. lncRNA myosin heavy chain-associated RNA transcript (lncRNA Mhrt) is a long non-coding RNA transcribed from the antisense chain of myosin heavy chain 7. The m6A level increased in mice with heart failure, and demethylation by FTO could influence the secondary structure of the lncRNA Mhrt. Overexpression of FTO has been demonstrated to inhibit myocardial cell apoptosis triggered by hypoxia/reoxygenation by modulating the levels of m6A methylation in lncRNA Mhrt [62]. Hypoxic preconditioning (HPC) emerges as an effective strategy to improve the survival rate of cells subjected to hypoxic conditions. HPC has the capacity to suppress the expression level of caspase-3 and mitigate the apoptosis of myocardial cells triggered by hydrogen peroxide. This protective mechanism relies on the biological actions of METTL3, METTL14, and the lncRNA H19. METTL3 and METTL14 are capable of directly interacting with lncRNA H19, enhancing its m6A methylation levels, and thereby contributing to the protective role of HPC [63]. This suggests that the m6A methylation modification of lncRNA H19 is critical in the anti-apoptotic process of cardiac cells. Current research has established that m6A methylation modification plays a crucial role in regulating the biological processes of circRNA, including occurrence, translation, degradation, and cytoplasmic export, within various cell types [64–67]. The sequencing of circRNA in the heart has revealed the presence of m6A methylation modifications [68]. Evidence suggests that these m6A methylation modifications on circRNA also play a crucial role in myocardial cell apoptosis. Following myocardial ischemia and reperfusion injury, the expression of circ-ZNF609 was observed to be upregulated. The elimination of circ-ZNF609 resulted in a reduction in the rate of myocardial cell apoptosis and alleviated heart dysfunction. Further investigation revealed that circ-ZNF609 influences the survival rate of myocardial cells by mediating the crosstalk between the Hippo-YAP signaling pathway and the protein kinase B (Akt) signaling pathway. YTHDF3 can directly interact with circ-ZNF609 and modulate the interplay among YAP, YTHDF1, and YTHDF2, thereby facilitating the nuclear translocation and translation of YAP, mediating the crosstalk between the Hippo-YAP signaling pathway and the AKT signaling pathway [69]. Pyroptosis is a form of inflammatory programmed cell death, distinguished by the swift rupture of the plasma membrane, which leads to the discharge of cellular contents and pro-inflammatory mediators [70]. Nod-like receptor protein 3 (NLRP3) belongs to the Nod-like receptor family and is a crucial component of the inflammasome, which is a key protein in cellular pyroptosis. YTHDF2 can recognize lncRNA terminal differentiation-induced lncRNA (lncRNA TINCR) that has undergone m6A methylation modification and accelerate its degradation, thereby inhibiting the expression of lncRNA TINCR and targeting NLRP3 to participate in myocardial cell pyroptosis [71]. In addition, the m6A methylation modification of pri-miRNA is also involved in the process of myocardial cell pyroptosis. During cardiac ischemia–reperfusion injury, silencing METTL3 reduced myocardial damage and inhibited the expression levels of NLRP3, caspase-1, and gasdermin D-1 (GSDMD-1) as well as the inflammatory response. Conversely, overexpressing METTL3 increased the generation of mature miR-143-3p and inhibited the transcription of protein kinase C epsilon (PRKCE), thereby promoting the occurrence of myocardial cell pyroptosis [72]. Ferroptosis is a novel form of cellular demise, distinguished by the accumulation of iron ions and the process of lipid peroxidation [73]. Following doxorubicin treatment, the heart’s m6A modification levels were observed to rise. The m6A methyltransferase METTL14 was found to catalyze the m6A methylation of its downstream target, the lncRNA KCNQ1 overlapping transcript 1 (KCNQ1OT1). This process, mediated by IGF2BP1, regulates the stability of KCNQ1OT1 and suppresses the activity of miR-7-5p. Consequently, this enhances the levels of transferrin receptor and promotes the production of ROS-driven lipid peroxidation, ultimately resulting in myocardial cell ferroptosis [74]. m6A on ncRNAs in cardiac fibrosis Although m6A methylation modification is involved in the pathological process of cardiac fibrosis, the mechanism and function of m6A methylation modification of ncRNAs are still not clear. Research on m6A modification of ncRNAs in cardiac fibrosis primarily focuses on lncRNAs. lncRNA MetBil interacts with METTL3, and the former can inhibit the ubiquitination degradation of METTL3, thereby inducing the expression of type I collagen and promoting cardiac fibrosis [75]. In addition to m6A methyltransferases, there are lncRNAs that can bind to m6A reader proteins IGF2BP2 and play an anti-cardiac fibrosis role under high glucose conditions [76]. The knockdown of lncRNA small nucleolar RNA host gene 8 (SNHG8) can reduce the infarction area in myocardial infarction mice. METTL3 can promote the expression of lncRNA SNHG8 and its binding to polypyrimidine tract-binding protein 1 (PTBP1) via m6A methylation modification, thereby modulating delta-aminolevulinate synthase 2 (ALAS2) to enhance oxidative stress [77], and oxidative stress is one of the pathogenic mechanisms of cardiac fibrosis. lncRNA metastasis-associated lung adenocarcinoma transcript 1 (lncRNA MALAT1) acts as a molecular sponge for miR-145, thereby activating the TGFβ signaling pathway and promoting cardiac fibrosis following myocardial infarction [78]. lncRNA growth arrest-specific transcript 5 (lncRNA GAS5) is downregulated during the process of cardiac fibrosis. Moreover, overexpression of lncRNA GAS5 can inhibit cardiac fibrosis via the PTEN/MMP-2 signaling pathway [79]. It is noteworthy that during various tissue fibrosis processes, METTL3 and FTO have the ability to modulate associated lncRNAs. For instance, METTL3 can enhance the m6A methylation level of the lncRNA MALAT1, thereby increasing its expression; FTO reduces the m6A methylation modification of lncRNA GAS5 to inhibit its expression [80, 81]. Furthermore, additional long non-coding RNAs [82–85] (such as lncRNA Mhrt, lncRNA MIAT, lncRNA H19, and lncRNA KCNQ1OT1) also exert an influence on the progression of cardiac fibrosis. The above results suggest that the m6A methylation modification of lncRNAs may be a possible mechanism for the occurrence of cardiac fibrosis. Currently, there is no direct evidence that m6A modification of miRNAs is involved in the process of cardiac fibrosis; however, some of these miRNAs demonstrate regulatory potential. For instance, the aforementioned microRNAs (including miRNA-133a, miR-221/222, miR-503, and miR-143-3p) have also been implicated in the regulation of cardiac fibrosis [86–89]. Considering the regulatory impact of m6A methylation modification on various miRNAs, as well as its role in cardiac function, it is speculated that m6A methylation modification could influence multiple miRNAs, thereby participating in the process of cardiac fibrosis. Although there are studies on circRNAs in cardiac fibrosis, and it has been found that circCELF1 can promote the expression level of FTO in cardiac fibroblasts [90], there is no evidence that m6A methylation modification induces cardiac fibrosis through affecting the biological processing of circRNA. In summary, a potential correlation exists between m6A methylation modification and various ncRNAs, underscoring the importance of further investigation into their roles and mechanisms within the context of cardiac fibrosis. m6A on ncRNAs in vascular remodeling Vascular remodeling represents a pathological physiological process wherein the vascular wall experiences adaptive alterations, influenced by a complex interplay of various factors. Although it has been proven that m6A plays a role in vascular remodeling, the potential mechanism of m6A methylation modification in ncRNAs during vascular remodeling primarily focuses on miRNAs. The proliferation and migration of vascular endothelial cells, which are integral to vascular remodeling, are pivotal processes contributing to pathological cardiac remodeling. Experiments have shown that the proliferation of vascular endothelial cells is inseparable from the regulatory role of METTL14 on the maturation of miR-19a. In the atherosclerosis model, the expression of METTL14 is markedly elevated, and it interacts with the RNA-binding protein DGCR8 to enhance the expression of matured miR-19a, thereby stimulating the proliferation and migration of vascular endothelial cells [91]. Sun et al. utilized bioinformatics analysis to identify potential m6A motifs proximal to the splicing sites of primary miR-503 in mice's heart. It has been confirmed that the overexpression of METTL3 can trigger the maturation of miR-503 in vascular endothelial cells, indicating that m6A methylation modification of miRNAs may exert a regulatory influence on vascular remodelling [92]. The regulatory impact of m6A methylation on key ncRNAs in cardiovascular remodeling has been investigated to a certain degree. However, the evidence for the direct involvement of other non-coding RNAs in this regulatory mechanism remains ambiguous. It is not yet understood whether m6A methylation affects other cell types during vascular remodeling and what roles it plays in the progression of pathological cardiac remodeling. Further molecular biological approaches are required for a more comprehensive discussion and analysis (Table 2, Fig. 2). Table 2m6A on ncRNAs in the regulation of pathological cardiac remodelingCategoryIn vitro/in vivom6A enzymencRNARole in pathological cardiac remodelingReferencesPathological cardiac hypertrophyIn vitro and in vivoMETTL3miR-221/222Inhibited DKK2, increased the activation of Wnt/β-catenin[54]In vitro and in vivoMETTL3, YTHDF2piRNA CHAPIRInhibited m6A of Parp10 mRNA, enhanced PARP10 expression and led to NFATC4 nuclear accumulation[57]In vitroFTO, IGF2BP2miR-133aIGF2BP2 promoted miR-133a-AGO2-RISC complex accumulation and repressed miR-133a expression[59]In vitro and in vivoYTHDF2lncRNA MIATInactivated PPARα/CPT1-a axis[61]Myocardial apoptosisIn vitro and in vivoFTOlncRNA MhrtInhibited the expression of cleaved caspase-3 and Bax[62]In vitro and in vivoMETTL3, METTL14lncRNA H19HPC promoted the combination of METTL3, METTL14, and lncRNA H19[63]In vitro and in vivoYTHDF3circ-ZNF609Inactivated Hippo-YAP signaling pathway, inhibited AKT expression[69]Myocardial pyroptosisIn vitro and in vivoMETTL14, YTHDF2lncRNA TINCRReduced diabetic cardiomyopathy by inhibiting NLRP3[71]In vitro and in vivoMETTL3miR-143-3pInhibit PRKCE transcription, promoted GSDMD1, cleaved caspase-1, and NLRP3 expression[72]Myocardial ferroptosisIn vitroMETTL14, IGF2BP1lncRNA KCNQ1OT1Increased levels of transferrin receptor, promoted the uptake of iron and production of ROS[74]Cardiac fibrosisIn vitro and in vivoMETTL3lncRNA MetBilPromoted collagen deposition, cardiac fibroblast proliferation and activation[75]In vitro and in vivoIGF2BP2lncRNA AirnPromoted the expression of p53, reversed fibroblast–myofibroblast transition, aberrant cardiac fibroblasts' proliferation and deposition of collagen I[76]Vascular remodelingIn vitro and in vivoMETTL14miR-19aBound to DGCR8 to process miR-19a, promoted the proliferation and invasion of ASVEC[91]In vitro and in vivoMETTL3miR-503Decreased PGC-1β and SIRT3 expression, reduced mitochondrial homeostasis[92] m6A on ncRNAs in the regulation of pathological cardiac remodeling m6A regulates pathological cardiac remodeling via ncRNAs. During pathological cardiac remodeling, “Writers” can upregulate miR221/222, miR-143-3p, miR-19, miR-503, lncRNA H19, lncRNA KCNQ1OT1; interact with lncRNA MetBil and piRMA CHAPIR. “Erasers” can upregulate lncRNA Mhrt. “Readers” can upregulate miR-133a; identify m6A-modified lncRNA MIAT and circ-ZNF609; downregulate lncRNA TINCR; interact with lncRNA Airn m6A and ncRNAs mediating exercise benefits for the pathological cardiac remodeling Exercise mediates m6A in pathological cardiac remodeling Exercise, as a form of non-pharmacological therapy, has emerged as a vital element in cardiac rehabilitation. Various forms of exercise serve as mechanical stimuli, fostering the multiplication of heart muscle cells and aiding in the reduction of cardiovascular disease risk. Furthermore, exercise has the potential to foster cardiac regeneration by activating a network of cellular signaling pathways [93]. The molecular mechanisms that underpin exercise have recently attracted considerable interest, encompassing the identification of key factors and signaling pathways that are beneficial for heart health and potential therapeutic targets for cardiac diseases. Bioinformatics has revealed that during aerobic exercise, m6A regulatory factors play a crucial role in lowering the risk of cardiovascular diseases and are closely associated with the metabolic processes of low-density lipoprotein, high-density lipoprotein, and triglycerides by using a model based on different m6A regulatory factors [94]. Wang et al. have confirmed that exercise can regulate m6A methylation levels, and m6A methylation modification may act as a mediator in exercise-induced cardiac protection. Consistent endurance training diminishes global m6A levels within cardiac tissue, and METTL14 emerges as a pivotal regulatory molecule in exercise-induced cardiac hypertrophy, as well as playing a role in pathological cardiac remodeling processes. Treadmill exercise reduces the expression levels of METTL14, and the silencing of METTL14 triggers the activation of AKT expression by suppressing the m6A levels of PHLPP2, thus modulating cardiomyocyte proliferation and apoptosis [95]. Lactylation, a recently identified type of post-translational modification, is prevalent in mammalian cells and is modulated by lactate concentrations [96]. Although lactate is a key metabolic product after exercise and can promote protein lactylation modification, there is no consensus on whether exercise can improve pathological cardiac remodeling through lactylation modification. A study conducted on mice with cardiac ischemia–reperfusion injury revealed that swimming training effectively decreased lactate levels within cardiomyocytes and suppressed the expression of the YTHDF2 protein. This process involves the G3BP1 protein, which plays a role in the growth and apoptosis of cardiomyocytes, thereby enhancing myocardial cell survival and cardiac function [97]. Interestingly, another research study has shown that exercise training can elevate m6A levels within the hearts of mice with heart failure with preserved ejection fraction (HFpEF). HFpEF + exercise training mouse hearts have more m6A peaks than HFpEF mouse heart samples and exercise training ameliorates myocardial apoptosis in heart failure with preserved ejection fraction by decreasing the apoptosis pathway and increasing myocardial energy metabolism. Exercise training suppresses the protein expression of FTO, thereby enhancing pathological cardiac hypertrophy, reducing cardiomyocyte apoptosis, and alleviating myocardial fibrosis [98]. There are several key possible reasons for this discrepancy. First, the fundamental difference between disease models and healthy models: HFpEF is a pathological state in which baseline m6A levels may already be dysregulated, and exercise may correct this dysregulation. In contrast, Wang et al.'s study observed exercise-induced physiological adaptations in healthy hearts. Second, the differences in exercise modalities: swimming training and treadmill exercise may impose different loads on the heart and involve distinct adaptation mechanisms. The most critical factor may be the differences in molecular mechanisms: in HFpEF, downregulation of FTO leads to increased m6A levels, whereas in exercise-induced physiological cardiac hypertrophy from swimming training, downregulation of METTL14 leads to decreased m6A levels. This suggests that different enzymes play dominant roles in different pathophysiological states. The two studies explain that m6A modification plays a context-dependent bidirectional regulatory role in exercise-induced cardiac adaptation. In disease states, exercise may elevate m6A levels to suppress abnormal signaling pathways, while in healthy states, exercise reduces m6A levels to promote physiological growth. To sum up, these discoveries offer novel perspectives on the correlation between physical activity and m6A modification levels. Exercise improves pathological cardiac remodeling by regulating m6A of ncRNAs Extensive research has been conducted on the molecular mechanisms through which ncRNA (such as miRNAs, lncRNAs and circRNAs) facilitate the protective effects of exercise on the heart, and this topic will not be explored further here [5]. The aforementioned reports indicate that exercise can influence epigenetic alterations in pathological cardiac remodeling via m6A methylation modifications. However, it remains unclear whether ncRNAs mediate this process. Vascular endothelial cell damage signifies the onset of atherosclerosis, and exercise is regarded as a crucial method for alleviating the condition. During the inflammatory state of vascular endothelial cells, the expression level of METTL14 is upregulated. It binds to the m6A site of lncRNA NEAT1 and, through the recognition of YTHDC1, further promotes the expression of lncRNA NEAT1. Subsequently, the lncRNA NEAT1 interacts with KLF4, modulates the transcription of NLRP3, and thereby facilitates the pyroptosis of vascular endothelial cells. In contrast, long-term regular aerobic exercise can reverse this series of processes [99]. It is evident that the m6A methylation modification of ncRNA may serve as a potential regulatory mechanism through which exercise improves pathological cardiac remodeling and mitigates cardiovascular disease (Fig. 3). m6A and ncRNAs mediating exercise benefits for the pathological cardiac remodeling. In the exercise-induced cardiac hypertrophy, exercise downregulates METTL14 expression to promote cardiomyocyte survival, and improve growth. Exercise downregulates lactylation modification to inhibit YTHDF2, thereby improving cardiac function; exercise can also downregulate FTO, suppress cardiomyocyte apoptosis, enhance mitochondrial integrity and function; exercise promotes m6A modification of lncRNA NEAT1 via METTL14, which is recognized by YTHDC1, leading to the downregulation of lncRNA NEAT1 expression and the inhibition of apoptosis Although the sample size of the current research is limited, considering the diverse trends of m6A levels identified in various models of pathological cardiac remodeling, and the heart’s highly intricate response to exercise, it is imperative to conduct further research into whether m6A modification can influence the development of pathological cardiac remodeling via ncRNAs in the context of exercise. To enhance the practical significance of these findings, future studies could utilize cardiomyocyte-specific METTL3/METTL14 or FTO/ALKBH5 knockout mice subjected to exercise to pinpoint the core regulators. On this basis, MeRIP-seq (or miCLIP) and RNA-seq transcriptomic analyses could be employed in exercised hearts to identify key exercise-responsive m6A-modified ncRNAs. Furthermore, gain- and loss-of-function studies should be conducted on candidate ncRNAs both in vitro and in vivo to validate their functional roles in exercise-induced benefits. Conclusion and perspective m6A methylation modification plays a regulatory role in ncRNAs implicated in pathological cardiac remodeling. m6A enzymes exert intricate control over ncRNAs, including the facilitation of miRNA maturation by converting pri-miRNAs into pre-miRNAs and ultimately mature miRNAs, as well as modulating the structural integrity and stability of lncRNAs. However, the mechanism of m6A has not been fully described, and the synergistic relationship between various signaling pathways remains to be further explored. These actions significantly impact a spectrum of pathological cardiac alterations, thereby charting novel avenues in the realm of epigenetics for the study of pathological cardiac remodeling. Exercise rehabilitation is a pivotal and widely accepted therapeutic approach for cardiac health. It regulates the expression of METTL14, YTHDF2, FTO, and YTHDC1, thereby inhibiting cardiomyocyte apoptosis, promoting cell growth, and improving energy metabolism. Notably, exercise modulates the recently discovered lncRNA NEAT1. However, inconsistent m6A trends across disease models necessitate further exercise intervention studies to clarify its role. These m6A-mediated epigenetic modifications represent a promising research area, underscoring exercise's potential to remodel the epigenetic landscape. Therefore, looking forward, we identify four emerging research priorities. First, further exploration is needed into the diverse research dimensions of m6A modifications on ncRNAs within the context of pathological cardiac remodeling. Although we have discussed several types of ncRNAs involved in pathological cardiac remodeling, the role of m6A modifications of ncRNAs in regulating mitochondrial homeostasis and the DNA damage response has been less reported and represents a novel and interesting research direction. Both processes are increasingly recognized as critical factors in cardiac aging and remodeling. Recent studies have identified several ncRNAs enriched in the heart that influence mitochondrial translation and oxidative stress tolerance. For instance, the lncRNA LIPCAR has been identified as a biomarker reflecting cardiomyocyte injury or mitochondrial dysfunction [100]; the lncRNA Caren-mediated mitochondrial biogenesis coupled with attenuated DNA damage response serves as a key mechanism delaying cardiac aging [101, 102]; and LncCIRBIL activates the transcription of pro-apoptotic genes, thereby inducing cardiomyocyte apoptosis [103]. Second, while current studies have predominantly focused on miRNAs and lncRNAs, it is essential to expand the scope of investigation to include other ncRNAs—such as circRNAs and piRNAs—in order to elucidate broader regulatory networks. Third, deeper mechanistic insight into exercise-induced cardioprotection is warranted, particularly through systematic identification and validation of downstream m6A targets and their functional ncRNAs. Finally, translational validation should be prioritized, since most existing findings derive from animal models, future research should emphasize human studies utilizing clinical samples and exercise interventions to facilitate therapeutic applications. Addressing these gaps will not only advance mechanistic knowledge, but also accelerate the development of m6A-based diagnostic and therapeutic strategies for cardiac disease. Acknowledgements We thank all authors for their ideas for the structure of the manuscript and for their contributions to writing and editing; all figures were created with BioRender.com. Author contributions Gonghua Yin: Writing—review & editing, Writing—original draft, Software, Data curation. Xiangfeng He: Writing—review & editing, Writing—original draft, Software. Nan Chen: Writing—review & editing, Validation, Supervision, Funding acquisition. All authors reviewed the manuscript. Funding This work was supported by the Shanghai “Rising Stars of Medical Talent” Youth Development Program for Outstanding Youth Medical Talents (SHWSRS2025-71); the Research Projects of Shanghai Municipal Health Commission “Research on early screening and intervention strategies for cognitive impairment in community-dwelling older people with sarcopenia” (No. 20254Z0006); and the Research Projects of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine “The Role and Mechanisms of Parabacteroides_goldsteinii on exercise in older people with sarcopenia” (No. PT82102651). Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Gonghua Yin and Xiangfeng He have contributed equally to this work and share first authorship. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.